5 withdrawn. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Withdrawn 5 |
Follow Liposarcoma: new trials by email Literature Review of Liposarcoma trials Research Report on Liposarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab Pembrolizumab, Pembrolizumab and Olaparib, Pembrolizumab adjuvant - Cancer | Phase 2 | Withdrawn | Gustave Roussy, Cancer Campus, Grand Paris | 2025-01-01 | 2025-12-01 | |
| Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma Gemcitabine, 9-ING-41, Docetaxel - Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma | Phase 2 | Withdrawn | Brown University | 2022-03-01 | 2021-12-07 | |
| A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas Gemcitabine, Docetaxel, 9-ING-41 - Sarcoma, Soft Tissue Sarcoma | Phase 2 | Withdrawn | Brown University | 2021-09-01 | 2021-07-28 | |
| Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma Biopsy, Laboratory Biomarker Analysis, Trabectedin - Myxoid Liposarcoma, Round Cell Liposarcoma | Phase 2 | Withdrawn | Fred Hutchinson Cancer Center | 2018-06-19 | 2019-09-10 | |
| Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma IPI-504 - Dedifferentiated Liposarcoma | Phase 2 | Withdrawn | Infinity Pharmaceuticals, Inc. | 2010-01-01 | 2015-04-14 |
Sarcoma (4) · Bone Neoplasms (2) · Dermatofibrosarcoma (2) · Hemangiosarcoma (2) · Histiocytoma, Malignant Fibrous (2) · Leiomyosarcoma (2) · Rhabdomyosarcoma (2) · Sarcoma, Synovial (2) · Liposarcoma, Myxoid (1) · Neoplasms (1) · Osteosarcoma (1)
Neoplasms by Histologic Type (5) · Neoplasms, Adipose Tissue (5) · Neoplasms, Connective and Soft Tissue (5) · Neoplasms (4) · Bone Diseases (2) · Fibrosarcoma (2) · Histiocytoma (2) · Musculoskeletal Diseases (2) · Myosarcoma (2) · Neoplasms by Site (2) · Neoplasms, Connective Tissue (2) · Neoplasms, Fibrous Tissue (2) · Neoplasms, Muscle Tissue (2) · Neoplasms, Vascular Tissue (2)
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione (2) · Docetaxel (2) · Gemcitabine (2) · Adjuvants, Pharmaceutic (1) · Biopsy (1) · Trabectedin (1) · olaparib (1) · pembrolizumab (1) · tanespimycin (1)
Brown University (2) · Fred Hutchinson Cancer Center (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Infinity Pharmaceuticals, Inc. (1)
United States (4) · France (1)
Bradley D DeNardo, MD (1) · Bradley DeNardo, MD (1) · Don S Dizon, MD (1) · Galina G Lagos, MD (1) · Seth Pollack (1)
P30CA015704 (1)